Loading... Please wait... Loading... Please wait...
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommend...
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience....
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Admini...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotec...
Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google....
Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public....
One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital So...
Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the l...
Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq....
